Targeting the MAPK Pathway in BRAF+ Melanoma
In melanoma, BRAF mutations have been demonstrated to hyperactivate MAPK pathway signaling, leading to tumor proliferation and growth.1,2 Targeted inhibition of protein kinases in this pathway has been shown to increase antitumor activity in melanoma, reversing some of the effects caused by BRAF mutations.2-8
Watch the video below to learn more about the potential of MAPK inhibition in melanoma.
Combined Inhibition of MAPK and PD-1 in Melanoma
For information on Novartis research in melanoma, please visit the Pipeline Navigator.
Acronyms: BRAF = v-raf murine sarcoma viral oncogene homolog B1; CRAF = cellular RAF proto-oncogene; ERK = extracellular signal-regulated kinase; MAPK = mitogen-activated protein kinase; MEK = mitogen-activated extracellular signal-regulated kinase; RTK = receptor tyrosine kinase.
References: 1. Sullivan RJ, Flaherty K. Oncogene. 2013;32:2372-2379. 2. Davies H, Bignell GR, Cox C, et al. Nature. 2002;417:949-954. 3. Mandala M, De Logu F, Merelli B, et al. Lab Invest. 2017;97:166-175. 4. Frederick DT, Piris A, Cogdill AP, et al. Clin Cancer Res. 2013;19:1225-1231. 5. Wilmott JS, Long GV, Howle JR, et al. Clin Cancer Res. 2012;18:1386-1394. 6. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Sci Transl Med. 2015;7(279):1-11. 7. Boni A, Cogdill AP, Dang P, et al. Cancer Res. 2010;70:5213-5219. 8. Ferrari de Andrade L, Ngiow SF, Stannard K, et al. Cancer Res. 2014;74:7298-7308.